Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Potential Allergenicity of New Wheat Varieties

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 1 year to 21 years of any sex and any race~* Physician-diagnosed food allergy to wheat with convincing clinical history of food allergy to wheat AND a skin prick test positive to wheat (diameter of wheal 3 mm or greater than negative control) or a detectable serum food-specific IgE level (ImmunoCAP \> 0.35 kUA/L) to wheat within the previous 12 months or at the time of entry into the study~* If no history of clinical reactivity to wheat, then a positive skin prick test to wheat (diameter of wheal 3 mm or greater than negative control) OR a detectable serum food-specific IgE level to wheat within the previous 12 months or at the time of entry into the study~* Patients who meet any of the following criteria are eligible for enrollment as study participants if they meet all other criteria, but will not undergo a DBPCFC:~  * Recent (within one year) failed open OFC~ * Positive DBPCFC to wheat at CHCO~ * Recent (within one year) exposure to wheat resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing, respiratory compromise, hypoxia, hypotension)~* Written informed consent from parent/guardian and assent (when age appropriate).~* Willingness to submit specimen for laboratory serum IgE testing~* Willingness to submit lab specimen for ELISA testing~Exclusion Criteria:~* Inability to discontinue antihistamines for skin prick testing and OFCs~* FEV1 value \<80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma, at the time of entry into the study~* Use of \>500 μg/day fluticasone or equivalent~* Asthma requiring either:~  * 1 hospitalization in the past year for asthma, or~ * 1 ER visit in the past 6 months for asthma~* Use of steroid medications (IV, IM or oral) for asthma in the following manners:~  * history of daily oral steroid dosing for \>1 month during the past year, or~ * steroid course/burst in the past 3 months (except for steroid dosing used in the treatment of an allergic reaction during the DBPCFC), or~ * 2 steroid courses/bursts in the past year.~* History of intubation due to allergies or asthma~* Diagnosis of active eosinophilic gastrointestinal disease in the past year~* Severe atopic dermatitis, as assessed by a Three-Item Severity Score of 6 or greater

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).